iBio (IBIO) Corporate presentation summary

Strategic positioning

• Strategy targets gaps beyond incretin therapies, including durable weight loss, fat-specific reduction, lean-mass preservation, tolerability, and dosing convenience.

• Portfolio includes 4 high-novelty programs and 1 partnered program; discovery-to-development candidate has taken as little as 7 months.

• Lead programs are IBIO-610, a long-acting Activin E antibody; IBIO-600, a long-acting myostatin antibody; and IBIO-800, a myostatin × Activin A bispecific.

IBIO-610

• Obese NHP studies showed a 33.2-day terminal half-life and ≥97% suppression of active Activin E at week 8 after a 10 mg/kg IV dose.

• At week 16, NHP body composition changed by -6.7% visceral fat, -5.2% total fat mass, and +0.9% total lean mass after two 10 mg/kg IV doses.

• With semaglutide in obese NHPs, lean tissue was 6% of mass lost versus 22% with semaglutide alone.

• IND-equivalent filing expected in 2H 2026; first patient dosing expected in 1H 2027.

IBIO-600

• Dual myostatin and GDF11 blockade is designed to support lean-mass preservation and fat-mass reduction; NHP half-life was 52.4 days after a single dose.

• Phase 1 SAD enrollment was complete as of June 2026; the randomized, placebo-controlled study in adults with overweight or obesity evaluates safety, tolerability, and human PK, with MAD cohorts planned.

• Interim Phase 1 data are anticipated in 1Q 2027.